This trial is active, not recruiting.

Condition benign prostatic hyperplasia
Sponsor Taipei Medical University WanFang Hospital
Start date December 2010
End date December 2013
Trial size 855 participants
Trial identifier NCT01351987, 100006


To analyze the change in International Prostate Symptom Score (IPSS) and serum prostate-specific antigen (PSA) level from baseline.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only

Eligibility Criteria

Male participants at least 50 years old.

Inclusion Criteria: - Males, age ≧ 50 years - Clinical diagnosis of BPH by medical history and physical examination, including a digital rectal examination (DRE) - IPSS score ≧ 8 points and prostate volume ≧ 30 mL - Total serum PSA ≧ 4.0 ng/mL and ≦ 20 ng/mL at screening - Previous TRUS-guided biopsy have been done with benign findings and with prostate cancer (CaP) not detected within the past 6 months. - Dutasteride combination therapy will be allowed by investigator's prescription - Ability to understand and willingly provide written informed consent Exclusion Criteria: - History or evidence of prostate cancer and high grade prostatic intraepithelial neoplasia (HGPIN) - With symptomatic urinary tract or prostate infection or urinary retention within 3 months prior to entry of study - Use of finasteride within 6 months of screening visit - Use of dutasteride within 12 months of screening visit

Additional Information

Official title An Observational Study of Dutasteride and Alpha-Blocker Combination Therapy in Men With Symptomatic Benign Prostatic Hyperplasia and PSA Level Over 4 ng/mL
Principal investigator Liang-Ming Lee
Description This is a non-interventional, observational and multicenter study. When subjects will be allowed the dutasteride and α-blocker orally once daily for two years by investigator's prescription. They will be invited to this observational study. All eligible subjects can be allowed the prior alpha blockers therapy. Details of acute urinary retention (AUR) and BPH-related prostatic surgery episodes will be recorded at every visit. Subjects will return to the clinic for assessment every 3 months until week 96. The efficacy and safety of combining the 5α-reductase inhibitor (5ARI), dutasteride, and the α-blocker will be assessed.
Trial information was received from ClinicalTrials.gov and was last updated in May 2011.
Information provided to ClinicalTrials.gov by Taipei Medical University WanFang Hospital.